The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Lysosomal Storage Disease (LSD) Market Research Report 2025
Synopsis
Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
The global Lysosomal Storage Disease (LSD) market was valued at US$ 7436.7 million in 2023 and is anticipated to reach US$ 10460 million by 2030, witnessing a CAGR of 4.9% during the forecast period 2024-2030.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
This report aims to provide a comprehensive presentation of the global market for Lysosomal Storage Disease (LSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lysosomal Storage Disease (LSD).
Report Scope
The Lysosomal Storage Disease (LSD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lysosomal Storage Disease (LSD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lysosomal Storage Disease (LSD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Actelion Pharmaceuticals
Amicus Therapeutics
Arena Pharmaceuticals
Astellas Pharma
Astrazeneca
Biomarin Pharmaceutical
Eli Lilly
Lexicon Pharmaceuticals
Novo Nordisk
Merck
Segment by Type
Lipid Metabolism Disorder
Glycoprotein Metabolism Disorder
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lysosomal Storage Disease (LSD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
The global Lysosomal Storage Disease (LSD) market was valued at US$ 7436.7 million in 2023 and is anticipated to reach US$ 10460 million by 2030, witnessing a CAGR of 4.9% during the forecast period 2024-2030.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
This report aims to provide a comprehensive presentation of the global market for Lysosomal Storage Disease (LSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lysosomal Storage Disease (LSD).
Report Scope
The Lysosomal Storage Disease (LSD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lysosomal Storage Disease (LSD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lysosomal Storage Disease (LSD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Actelion Pharmaceuticals
Amicus Therapeutics
Arena Pharmaceuticals
Astellas Pharma
Astrazeneca
Biomarin Pharmaceutical
Eli Lilly
Lexicon Pharmaceuticals
Novo Nordisk
Merck
Segment by Type
Lipid Metabolism Disorder
Glycoprotein Metabolism Disorder
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lysosomal Storage Disease (LSD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lysosomal Storage Disease (LSD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Lipid Metabolism Disorder
1.2.3 Glycoprotein Metabolism Disorder
1.3 Market by Application
1.3.1 Global Lysosomal Storage Disease (LSD) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lysosomal Storage Disease (LSD) Market Perspective (2019-2030)
2.2 Lysosomal Storage Disease (LSD) Growth Trends by Region
2.2.1 Global Lysosomal Storage Disease (LSD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Lysosomal Storage Disease (LSD) Historic Market Size by Region (2019-2024)
2.2.3 Lysosomal Storage Disease (LSD) Forecasted Market Size by Region (2025-2030)
2.3 Lysosomal Storage Disease (LSD) Market Dynamics
2.3.1 Lysosomal Storage Disease (LSD) Industry Trends
2.3.2 Lysosomal Storage Disease (LSD) Market Drivers
2.3.3 Lysosomal Storage Disease (LSD) Market Challenges
2.3.4 Lysosomal Storage Disease (LSD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lysosomal Storage Disease (LSD) Players by Revenue
3.1.1 Global Top Lysosomal Storage Disease (LSD) Players by Revenue (2019-2024)
3.1.2 Global Lysosomal Storage Disease (LSD) Revenue Market Share by Players (2019-2024)
3.2 Global Lysosomal Storage Disease (LSD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Lysosomal Storage Disease (LSD) Revenue
3.4 Global Lysosomal Storage Disease (LSD) Market Concentration Ratio
3.4.1 Global Lysosomal Storage Disease (LSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lysosomal Storage Disease (LSD) Revenue in 2023
3.5 Lysosomal Storage Disease (LSD) Key Players Head office and Area Served
3.6 Key Players Lysosomal Storage Disease (LSD) Product Solution and Service
3.7 Date of Enter into Lysosomal Storage Disease (LSD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lysosomal Storage Disease (LSD) Breakdown Data by Type
4.1 Global Lysosomal Storage Disease (LSD) Historic Market Size by Type (2019-2024)
4.2 Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Type (2025-2030)
5 Lysosomal Storage Disease (LSD) Breakdown Data by Application
5.1 Global Lysosomal Storage Disease (LSD) Historic Market Size by Application (2019-2024)
5.2 Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Lysosomal Storage Disease (LSD) Market Size (2019-2030)
6.2 North America Lysosomal Storage Disease (LSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Lysosomal Storage Disease (LSD) Market Size by Country (2019-2024)
6.4 North America Lysosomal Storage Disease (LSD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lysosomal Storage Disease (LSD) Market Size (2019-2030)
7.2 Europe Lysosomal Storage Disease (LSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Lysosomal Storage Disease (LSD) Market Size by Country (2019-2024)
7.4 Europe Lysosomal Storage Disease (LSD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size (2019-2030)
8.2 Asia-Pacific Lysosomal Storage Disease (LSD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lysosomal Storage Disease (LSD) Market Size (2019-2030)
9.2 Latin America Lysosomal Storage Disease (LSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Lysosomal Storage Disease (LSD) Market Size by Country (2019-2024)
9.4 Latin America Lysosomal Storage Disease (LSD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size (2019-2030)
10.2 Middle East & Africa Lysosomal Storage Disease (LSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Actelion Pharmaceuticals
11.1.1 Actelion Pharmaceuticals Company Detail
11.1.2 Actelion Pharmaceuticals Business Overview
11.1.3 Actelion Pharmaceuticals Lysosomal Storage Disease (LSD) Introduction
11.1.4 Actelion Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.1.5 Actelion Pharmaceuticals Recent Development
11.2 Amicus Therapeutics
11.2.1 Amicus Therapeutics Company Detail
11.2.2 Amicus Therapeutics Business Overview
11.2.3 Amicus Therapeutics Lysosomal Storage Disease (LSD) Introduction
11.2.4 Amicus Therapeutics Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.2.5 Amicus Therapeutics Recent Development
11.3 Arena Pharmaceuticals
11.3.1 Arena Pharmaceuticals Company Detail
11.3.2 Arena Pharmaceuticals Business Overview
11.3.3 Arena Pharmaceuticals Lysosomal Storage Disease (LSD) Introduction
11.3.4 Arena Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.3.5 Arena Pharmaceuticals Recent Development
11.4 Astellas Pharma
11.4.1 Astellas Pharma Company Detail
11.4.2 Astellas Pharma Business Overview
11.4.3 Astellas Pharma Lysosomal Storage Disease (LSD) Introduction
11.4.4 Astellas Pharma Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.4.5 Astellas Pharma Recent Development
11.5 Astrazeneca
11.5.1 Astrazeneca Company Detail
11.5.2 Astrazeneca Business Overview
11.5.3 Astrazeneca Lysosomal Storage Disease (LSD) Introduction
11.5.4 Astrazeneca Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.5.5 Astrazeneca Recent Development
11.6 Biomarin Pharmaceutical
11.6.1 Biomarin Pharmaceutical Company Detail
11.6.2 Biomarin Pharmaceutical Business Overview
11.6.3 Biomarin Pharmaceutical Lysosomal Storage Disease (LSD) Introduction
11.6.4 Biomarin Pharmaceutical Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.6.5 Biomarin Pharmaceutical Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Detail
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Lysosomal Storage Disease (LSD) Introduction
11.7.4 Eli Lilly Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.7.5 Eli Lilly Recent Development
11.8 Lexicon Pharmaceuticals
11.8.1 Lexicon Pharmaceuticals Company Detail
11.8.2 Lexicon Pharmaceuticals Business Overview
11.8.3 Lexicon Pharmaceuticals Lysosomal Storage Disease (LSD) Introduction
11.8.4 Lexicon Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.8.5 Lexicon Pharmaceuticals Recent Development
11.9 Novo Nordisk
11.9.1 Novo Nordisk Company Detail
11.9.2 Novo Nordisk Business Overview
11.9.3 Novo Nordisk Lysosomal Storage Disease (LSD) Introduction
11.9.4 Novo Nordisk Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.9.5 Novo Nordisk Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Lysosomal Storage Disease (LSD) Introduction
11.10.4 Merck Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024)
11.10.5 Merck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
